Antithrombotic therapy in cardiac embolism
- PMID: 21804782
- PMCID: PMC2994115
- DOI: 10.2174/157340310791658749
Antithrombotic therapy in cardiac embolism
Abstract
Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is safe even in moderate acute strokes. The efficacy of early anticoagulation after cardioembolic stroke in relation to outcome has not been assessed adequately, but there is evidence from animal models and clinical studies that anticoagulation with unfractionated heparin is associated with a better outcome mediated in part by its anti-inflammatory properties.
Keywords: Anticoagulation; heparin; inflammation.; oral anticoagulants; prevention.
References
-
- Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25(5):457–507. - PubMed
-
- Cervera A, Amaro S, Obach V, Chamorro A. Prevention of ischemic stroke: antithrombotic therapy in cardiac embolism. Curr Drug Targets. 2007;8(7):824–31. - PubMed
-
- Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371–7. - PubMed
-
- Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 Suppl):630S–69S. - PubMed
-
- Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 Suppl):257S–98S. - PubMed
LinkOut - more resources
Full Text Sources
